Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior

  • LANXESS impairs parts of its goodwill
  • Adjustment of at-equity book value of minority interest in Envalior 
  • EBITDA pre exceptionals for Full Year 2023 remains within market expectations 
     
Cologne
During the preparation of annual financial statements for the year 2023, LANXESS identified an impairment requirement on goodwill amounting to EUR 413 million. The impairment incurred in the Business Units Flavors & Fragrances and Polymer Additives and reduces the goodwill recognized as part of the acquisitions. The reason for the impairment is a demand that has partly developed weaker than expected in the respective Business Units, especially for the years 2023 and 2024.  

In the course of the parallel and ongoing preparation of the financial statements at our joint venture Envalior, we also foresee the necessity of a material value reduction of our minority interest. This will likely result in a low to medium triple-digit million EUR amount. 

The impairment analyses are not completed and not yet finally audited. 

Neither the recognition of the impairment charges at LANXESS nor the reduction of the value of our minority interest have an effect on our EBITDA pre exceptionals, and are not cash relevant. 

LANXESS will report its results for Full Year 2023 on 14 March 2024. EBITDA pre exceptionals is expected to be in line with market expectations. The consensus (Vara) for EBITDA pre exceptionals is currently at EUR 510 million.
 

Information for editors:
All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

You can find further information concerning LANXESS chemistry at http://lanxess.com/en/Media/Stories.

MORE ABOUT THIS TOPIC

PRESS RELEASE
Since August 1, 2013, specialty chemicals Group LANXESS is steering its global business from the LANXESS Tower in Cologne.

Rainier van Roessel re-elected Chairman

May 21, 2026
PRESS RELEASE
Since August 1, 2013, specialty chemicals Group LANXESS is steering its global business from the LANXESS Tower in Cologne.

LANXESS confirms guidance despite subdued start to the year

May 07, 2026
PRESS RELEASE
Three-stage ion exchange resin vessel cascade for adsorption of short-chain PFAS at Chemours in Dordrecht, South Holland (Netherlands).

PFAS Removal: LANXESS Selective Resin Proves Its Worth in Industrial Use

May 05, 2026
PRESS RELEASE
Glass bottles with fragrances

LANXESS showcases innovative aroma ingredients at SIMPPAR 2026

May 05, 2026
PRESS RELEASE
LANXESS corporate headquarters in Cologne

LANXESS once again leads the European Dow Jones Best-in-Class Index

May 01, 2026